86 withdrawn. 86 Phase 2, 15 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 86 | Withdrawn 86 |
| Phase 1 | 15 | Withdrawn 15 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Neoplasm Metastasis: new trials by email Literature Review of Neoplasm Metastasis trials Research Report on Neoplasm Metastasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma 9-ING-41, Carboplatin - Salivary Gland Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Withdrawn | Actuate Therapeutics Inc. | 2030-12-18 | 2022-02-22 | |
| Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp Dexamethasone - Uveal Melanoma, Metastatic | Phase 2 | Withdrawn | University of California, San Diego | 2026-11-01 | 2026-11-06 | |
| Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With Active Brain Metastases Datopotamab deruxtecan - Non-small Cell Lung Cancer | Phase 2 | Withdrawn | MedSIR | 2025-06-01 | 2025-08-08 | |
| The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial. Autologous hMSCs, Autologous Human C-Kit CSCs II, Placebo - Chronic Ischemic Left Ventricular Dysfunction, Myocardial Infarction | Phase 1 / Phase 2 | Withdrawn | Joshua M Hare | 2025-03-01 | 2020-10-22 | |
| A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01) Pembrolizumab, Favezelimab, Favezelimab/Pembrolizumab - Neoplasm Metastasis | Phase 1 / Phase 2 | Withdrawn | Merck Sharp & Dohme LLC | 2025-01-15 | 2025-04-08 | |
| Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. VB10.16, Atezolizumab Injection [Tecentriq], Placebo - HPV-Related Cervical Carcinoma, HPV-Related Malignancy | Phase 2 | Withdrawn | Nykode Therapeutics ASA | 2024-04-18 | 2024-09-20 | |
| A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients ONCOS-102, Balstilimab - Melanoma | Phase 2 | Withdrawn | Targovax Oy | 2024-01-01 | 2023-06-22 | |
| Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients Pre-Chemo-radio-immunotherapy Treatment (Nivolumab/Ipilimumab), Concurrent Chemo-radio-immunotherapy (Nivolumab/Ipilimumab), Maintenance Treatment (Nivolumab/Ipilimumab) - Cervical Cancer ≥ FIGO IIB and or Lymph Node Metastases | Phase 2 | Withdrawn | Universitätsklinikum Köln | 2023-11-01 | 2023-04-18 | |
| Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib Lorlatinib, Cisplatin or Carboplatin, Pemetrexed - Lung Cancer, Non-small Cell Lung Cancer | Phase 2 | Withdrawn | SCRI Development Innovations, LLC | 2023-11-01 | 2023-12-13 | |
| Fulvestrant + Neratinib In Breast Cancer NERATINIB, FULVESTRANT - Stage IV (Metastatic) Breast Cancer, Metastatic Breast Cancer | Phase 2 | Withdrawn | Massachusetts General Hospital | 2023-07-01 | 2023-08-01 | |
| Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin - Metastatic Cancer, Urothelial Carcinoma | Phase 2 | Withdrawn | AdventHealth | 2023-05-08 | 2024-08-01 | |
| Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer 700mg leronlimab weekly dose, 80mg Regorafenib at week 1, 120mg Regorafenib at week2 - CCR5, Microsatellite Stable | Phase 2 | Withdrawn | CytoDyn, Inc. | 2022-09-20 | 2023-02-17 | |
| Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Standard of Care Chemotherapy, Video-Assisted Thoracic Surgery (VATS), Lobectomy - Metastatic Cancer, Foregut Carcinoid Tumor | Phase 2 | Withdrawn | University of Chicago | 2022-05-19 | 2024-07-31 | |
| Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC Cetuximab - Lung Cancer, Surgery | Phase 2 | Withdrawn | The Netherlands Cancer Institute | 2022-01-01 | 2023-10-19 | |
| LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery LS301, Cancer Vision Goggles - Pancreatic Cancer, Liver Cancer | Phase 1 / Phase 2 | Withdrawn | Washington University School of Medicine | 2021-12-31 | 2021-12-09 | |
| Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer. Tucatinib - Breast Cancer Stage IV | Phase 1 / Phase 2 | Withdrawn | Providence Health & Services | 2021-12-15 | 2023-06-22 | |
| A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC NC318, Pemetrexed/Carboplatin, Nab paclitaxel/Carboplatin - Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Withdrawn | NextCure, Inc. | 2021-12-06 | 2021-08-18 | |
| Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma Niraparib, Dostarlimab - HRD, Cholangiocarcinoma | Phase 2 | Withdrawn | Walid Shaib, MD | 2021-10-11 | 2022-06-29 | |
| The P10s-PADRE Basket Trial: Vaccination of Metastatic Cancer Patients P10s-PADRE - Neoplasms by Site, Metastatic Cancer | Phase 2 | Withdrawn | University of Arkansas | 2021-03-01 | 2024-09-03 | |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers SNK01, Trastuzumab, Cetuximab - Advanced Solid Tumor, Metastatic Cancer | Phase 1 / Phase 2 | Withdrawn | NKGen Biotech, Inc. | 2021-03-01 | 2021-05-12 |
Showing 20 of 86. Sign in to see all of them.
Colorectal Neoplasms (13) · Neoplasms (11) · Breast Neoplasms (10) · Carcinoma, Non-Small-Cell Lung (10) · Recurrence (8) · Lung Neoplasms (7) · Prostatic Neoplasms (7) · Carcinoma, Renal Cell (6) · Rectal Neoplasms (5) · Adenocarcinoma (4) · Brain Neoplasms (4) · Liver Neoplasms (4) · Melanoma (4) · Pancreatic Neoplasms (4)
Pathologic Processes (86) · Pathological Conditions, Signs and Symptoms (86) · Neoplastic Processes (85) · Neoplasms (75) · Neoplasms by Site (65) · Neoplasms by Histologic Type (28) · Digestive System Diseases (23) · Digestive System Neoplasms (21) · Neoplasms, Glandular and Epithelial (21) · Gastrointestinal Diseases (19) · Carcinoma (17) · Urogenital Diseases (17) · Urogenital Neoplasms (17) · Gastrointestinal Neoplasms (16) · Respiratory Tract Diseases (15)
Docetaxel (6) · Oxaliplatin (6) · Fluorouracil (5) · Gemcitabine (5) · Nivolumab (5) · Bevacizumab (4) · Capecitabine (4) · Cetuximab (4) · Paclitaxel (4) · Carboplatin (3) · Leucovorin (3) · 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol (2) · Cisplatin (2) · Dexamethasone (2) · Erlotinib Hydrochloride (2)
Hadassah Medical Organization (4) · M.D. Anderson Cancer Center (3) · National Cancer Institute (NCI) (3) · Dana-Farber Cancer Institute (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · SCRI Development Innovations, LLC (2) · The University of Texas Health Science Center, Houston (2) · University of Medicine and Dentistry of New Jersey (2) · AHS Cancer Control Alberta (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Actuate Therapeutics Inc. (1) · AdventHealth (1) · AmpliMed Corporation (1) · Barretos Cancer Hospital (1)
United States (34) · France (4) · Netherlands (4) · Denmark (3) · Israel (3) · Germany (2) · Italy (2) · Belgium (1) · Brazil (1) · Canada (1) · China (1) · Greece (1) · Poland (1) · South Korea (1) · Spain (1)
Robert J Amato, DO (2) · Shimon Slavin, MD (2) · Aditya Bardia, MD,MPH (1) · Afshin Shafie, MD (1) · Alison Conlin, MD (1) · Ayman Gaber, MD (1) · Bertrand Tombal (1) · Brian Wolpin, MD, MPH (1) · Cathy Eng, MD (1) · Cora Sternberg (1) · David David (1) · David Hui, MD (1) · Dirk Elling, Professor (1)
PMID 20500867, PMID 20525328, PMID 23739633, PMID 29371475, PMID 31065624
2016 (2), P30CA072720 (2), 2014 (1), 2015 (1), 2018 (1), 2019 (1), 2023 (1), P30CA016058 (1), P30CA016672 (1), P30CA046934 (1), U01CA070172 (1), U10CA032102 (1), UM1CA186704 (1)